Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HP518, a PROTAC molecule targeting advanced prostate cancer; HP537, a small-molecule anti-tumor drug; HP515, an orally administered which improves liver and blood biochemical indicators; HP570, an orally administered molecular gel degrader targeting VAV1; and HC-X049, a small molecule project with STAT6 target layout. Hinova Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Chengdu, China.
Frequently asked questions
What sector does Hinova Pharmaceuticals Inc. A (688302) operate in?
Hinova Pharmaceuticals Inc. A belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Hinova Pharmaceuticals Inc. A (688302) current stock price?
As of the latest data, Hinova Pharmaceuticals Inc. A stock price is CN¥30.99, with a previous close of CN¥30.44. Hinova Pharmaceuticals Inc. A gained CN¥0.55 in the last trading session, representing a 1.81% increase.
What is Hinova Pharmaceuticals Inc. A (688302) current market capitalization?
Hinova Pharmaceuticals Inc. A market cap is approximately 3.07 billion.
What is Hinova Pharmaceuticals Inc. A (688302) Earnings Per Share (EPS)?
The trailing EPS is -CN¥1.34.
Does Hinova Pharmaceuticals Inc. A (688302) pay dividends?
No. Hinova Pharmaceuticals Inc. A does not pay a dividend.
What is Hinova Pharmaceuticals Inc. A (688302) beta (volatility) score?
Hinova Pharmaceuticals Inc. A has a beta of -0.068, indicating lower volatility than the overall market.
